Advertisement
WAUKESHA, Wis., May 26, 2020 /PRNewswire-PRWeb/ -- Coppe Healthcare Solutions (Coppe Laboratories), a CLIA Certified Laboratory based in Waukesha, Wisconsin, has acquired Open CoVIDx, the laboratory division of the Open Medicine Institute based in San Francisco Bay area of California.
The CEO of Coppe Laboratories is Dr. Konstance Knox, the Virologist who previously co-founded what is now Viracor-Eurofins in the year 2000. Dr. Knox has expanded Coppe's testing footprint to serve 1,000 Doctor's Offices in the United States, and internationally with a Coppe run Laboratory at the new 5,000 bed Hamptons Hospital, under development at Mwale Medical and Technology City (MMTC) in Kenya.
Open CoVIDx is a division of the Open Medicine Institute, founded by the current CEO, Dr. Andy Kogelnik. It has a 104,000 square foot facility in the biotech incubator at a former pharmaceutical campus in Mountain View, CA.
The merger will become Coppe-Open CoVIDx Laboratories, and will combine the laboratory capacities of the two for a total of 1.5 million COVID-19 diagnostic tests per month, by end of June 2020. The increased capacity will put Coppe among the top 5 COVID-19 testing Laboratories in the United States.
The merger will allow Coppe Laboratories to provide employers in the USA and Kenya with COVID-19 diagnostic testing for employees, environmental testing of work places, and antibody testing within the FDA approved guidelines.
For media inquiries please email [email protected] +1 262.574.5074 http://www.coppelabs.com
SOURCE Coppe Healthcare Solutions
Advertisement
The CEO of Coppe Laboratories is Dr. Konstance Knox, the Virologist who previously co-founded what is now Viracor-Eurofins in the year 2000. Dr. Knox has expanded Coppe's testing footprint to serve 1,000 Doctor's Offices in the United States, and internationally with a Coppe run Laboratory at the new 5,000 bed Hamptons Hospital, under development at Mwale Medical and Technology City (MMTC) in Kenya.
Open CoVIDx is a division of the Open Medicine Institute, founded by the current CEO, Dr. Andy Kogelnik. It has a 104,000 square foot facility in the biotech incubator at a former pharmaceutical campus in Mountain View, CA.
The merger will become Coppe-Open CoVIDx Laboratories, and will combine the laboratory capacities of the two for a total of 1.5 million COVID-19 diagnostic tests per month, by end of June 2020. The increased capacity will put Coppe among the top 5 COVID-19 testing Laboratories in the United States.
The merger will allow Coppe Laboratories to provide employers in the USA and Kenya with COVID-19 diagnostic testing for employees, environmental testing of work places, and antibody testing within the FDA approved guidelines.
For media inquiries please email [email protected] +1 262.574.5074 http://www.coppelabs.com
SOURCE Coppe Healthcare Solutions
